A Study of CPX-351 (Vyxeos™) With Quizartinib for the Treatment of FLT3-ITD Mutation-Positive Acute Myeloid Leukemia
- Registration Number
- NCT04209725
- Lead Sponsor
- SCRI Development Innovations, LLC
- Brief Summary
This is a research study to be done at multiple sites in participants with advanced acute myeloid leukemia (AML) that have a mutation in Fms-like tyrosine kinase-3 internal tandem duplications (FLT3-ITD). This study is to learn more about an investigational drug, quizartinib, being tested with the anti-cancer medicine CPX-351 (also called Vyxeos™), which is approved and widely used to treat AML.
The purpose of this study is to assess the safety, tolerability and survival of patients receiving the combination of CPX-351 and quizartinib.
- Detailed Description
This is an open-label, two-part Phase II clinical trial in patients with relapsed or refractory FLT3-ITD mutation-positive acute myeloid leukemia (AML). The study is designed to assess the safety and tolerability as well as the efficacy of administering CPX-351 (cytarabine:daunorubicin liposome complex) with quizartinib. CPX-351 is a formulation of two drugs, cytarabine and daunorubicin, that is administered as the first part of treatment to get rid of as many leukemia cells in your bone marrow as possible. Quizartinib is an investigational drug made of a protein that inhibits FLT3 and will be given after CPX-351 has been given. The plan for administration is divided into three phases: induction, consolidation, and maintenance.
Recruitment & Eligibility
- Status
- TERMINATED
- Sex
- All
- Target Recruitment
- 1
-
Written informed consent form (ICF), according to local guidelines, signed by the patient or by a legal guardian prior to the performance of any study-related screening procedures.
-
Patients with the following types of AML with >5% blasts:
- Relapsed FLT3-ITD mutation-positive AML, diagnosed by bone marrow (BM) biopsy with FLT3 mutation by polymerase chain reaction (PCR)
- Refractory FLT3-ITD mutation-positive AML, diagnosed by BM biopsy with FLT3 mutation by PCR
- Relapsed or refractory FLT3-ITD mutation-positive AML after HCT, diagnosed by BM biopsy with FLT3 mutation by PCR
- Relapsed or refractory AML with de novo FLT3-ITD mutation, diagnosed by BM biopsy with FLT3 mutation by PCR
- Relapsed or refractory AML after HCT with de novo FLT3-ITD mutation, diagnosed by BM biopsy with FLT3 mutation by PCR
-
First-line therapy must have contained a standard induction chemotherapy (e.g. 7+3, FLAG-IDA, FLAG, CLAG, MEC, hypomethylating agent with venetoclax) with or without receiving a prior FLT3 inhibitor (e.g. midostaurin) or multi-tyrosine kinase inhibitor (e.g. sorafenib). All patients who relapsed after an alloHCT are included, except patients with active graft-versus-host disease (GVHD) requiring >10 mg prednisone.
-
Patients must be able to swallow and retain oral medication.
-
Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0, 1, or 2 (Appendix A).
-
Adequate renal and hepatic parameters (aspartate aminotransferase [AST], alanine aminotransferase [ALT] ≤2.5 institutional upper limit of normal [ULN]; total bilirubin ≤2.0 institutional ULN; serum creatinine [Cr] ≤2.0). In patients with suspected liver infiltration, ALT can be ≤5 institutional ULN.
-
Acute promyelocytic leukemia (t[15;17])
-
Female patients who are lactating or have a positive serum pregnancy test during the screening period. Female patients of childbearing potential who are not willing to employ highly effective birth control (as defined in Appendix C of protocol) from screening to 6 months following the last dose of CPX-351 and/or quizartinib.
-
Evidence of active and uncontrolled bacterial, fungal, parasitic, or viral infection. Infections are considered controlled if appropriate therapy has been instituted and, at the time of screening, no signs of active infection progression are present. This is assessed by the site clinicians, including an infectious disease consulting physician, if requested by the Principal Investigator (PI), regarding adequacy of therapy. These infections include, but are not limited to:
- Known human immunodeficiency virus (HIV) infection
- Active hepatitis B or C infection with rising transaminase values
- Active tuberculosis infection
-
History of hypersensitivity to cytarabine, daunorubicin, or an FLT3 inhibitor
-
Any patients with known significant impairment in gastrointestinal (GI) function or GI disease that my significantly alter the absorption of quizartinib.
-
Psychological, familial, sociological, or geographical conditions that do not permit compliance with the protocol.
-
Uncontrolled or significant cardiovascular disease, including any of the following:
- Bradycardia of less than 50 beats per minute, unless the patient has a pacemaker
- QTcF interval using Fridericia's correction factor (QTcF) interval prolongation, defined as >450msec at screening and prior to first administration of quizartinib
- Diagnosis of or suspicion of long QT syndrome (including family history of long QT syndrome)
- Systolic blood pressure ≥180 mmHg or diastolic blood pressure ≥110 mmHg
- History of clinically relevant ventricular arrhythmias (i.e., ventricular tachycardia, ventricular fibrillation or Torsades de pointes)
- History of second or third degree heart block without a pacemaker
- Right bundle branch and left anterior hemiblock (bifascicular block), complete left bundle branch block
- Ejection fraction <50% by transthoracic echocardiogram (TTE) or multigated acquisition (MUGA) scan
- History of uncontrolled angina pectoris or myocardial infarction within 6 months prior to Screening
-
History of New York Heart Association Class 3 or 4 heart failure
-
Prior anthracycline (or equivalent) cumulative exposure ≥368 mg/m2 daunorubicin (or equivalent)
-
Any serious underlying medical condition that, in the opinion of the Investigator or Medical Monitor, would impair the ability to receive or tolerate the planned treatment.
-
Patients with inadequate adequate pulmonary function will be excluded. Inadequate pulmonary function is defined as requiring supplemental O2, or diffusing capacity of the lungs for carbon monoxide [DLCO] <40%.
-
Active acute or chronic GVHD requiring prednisone >10 mg or equivalent.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description CPX-351 and Quizartinib treatment CPX-351 Participants with FLT3 mutation positive AML will be given CPX-351 followed by quizartinib in three phases: induction, consolidation, and maintenance. CPX-351 and Quizartinib treatment Quizartinib Participants with FLT3 mutation positive AML will be given CPX-351 followed by quizartinib in three phases: induction, consolidation, and maintenance.
- Primary Outcome Measures
Name Time Method Number of Patients With Treatment Related Adverse Events After Taking CPX-351 and Quizartinib Collected during treatment and for 30 days after last dose, approximately 35 total days for the 1 patient treated. Counting the number of patients with treatment related adverse events as a measure of safety and tolerability.
Number of Patients With an Overall Response Taking CPX-351 and Quizartinib from cycle 1 day 1 (each cycle is 28 days) until disease progression for up to 2 years post treatment Overall response is defined by the International Working Group response criteria (Cheson et al 2003) as having a complete remission (CR) - a complete morphologic response with complete blood count recovery absolute neutrophil count ≥1000/μL and platelet count ≥100,000/μL) or a complete morphologic response with an incomplete blood count recovery (CRi) - absolute neutrophil count \<1000/μL and/or platelet count \<100,000/μL)
- Secondary Outcome Measures
Name Time Method Event-free Survival Time from day 1 for up to 4 years Defined as the number of days until evidence of PD by bone marrow biopsy/aspirate, or death, regardless of cause. Patients who are alive without a disease response assessment of relapsed disease will be censored at the last adequate disease assessment date. Patients without a disease response assessment will be censored at the first date of treatment.
Overall Survival (OS) Up to 8 months Overall survival is defined as the time from the first date of treatment until death as a result of any cause. For OS time, patients that have not died or are lost to follow-up will be censored at the date the patient was last known to be alive or the date of last contact.
Number of Patients Who Can Receive Consolidation and Maintenance Therapy approximately 3 months Patients who proceed through induction to next stages of consolidation and maintenance
Percentage of Patients Who Achieve a PR or Molecular Complete Remission from cycle 1 day 1 (each cycle is 28 days) until disease progression for up to 2 years post treatment A PR is defined as persistent disease by morphology but with a \>50% reduction in the blast count/cellularity ratio compared to the most recent BM biopsy prior to treatment. A molecular complete remission is defined as no evidence of disease by bone marrow biopsy/aspirate by morphology, immunohistochemistry, or flow cytometry, and FLT3 mutation by MRD analysis.
Mean Elapsed Time for Patients to Achieve Molecular CR From Date of First Treatment to up to 2 years The mean time to achievement of a complete morphologic CR with persistent disease detected by flow or molecular minimal residual disease (MRD) analysis.
Median Time to Platelet Count Recovery from cycle 1 Day 1 (each cycle is 28 days) for up to 24 months Time to platelet recovery is defined as the time to when the peripheral blood platelet count is \>50, 000/ μL
Number of Patients Who Develop Late Responses up to 4 years Late responses as defined by the International Working Group response criteria (Cheson et al 2003) as having a complete remission (CR) - a complete morphologic response with complete blood count recovery absolute neutrophil count ≥1000/μL and platelet count ≥100,000/μL) or a complete morphologic response with an incomplete blood count recovery (CRi) - absolute neutrophil count \<1000/μL and/or platelet count \<100,000/μL
Median Time to Absolute Neutrophil Count (ANC) Recovery from Cycle 1 Day 1 (each cycle is 28 days) for up to 24 months Time to neutrophil recovery is defined as the time to when the peripheral blood ANC is ≥500/μL
Number of Patients Proceeding to an Allogeneic Hematopoietic Cell Transplantation (alloHCT) up to 60 days after consolidation therapy Patients receiving allogeneic hematopoietic cell transplantation (alloHCT) following treatment in induction and consolidation therapies.
Median Time to Disease Progression from diagnosis of relapse or refractory AML until disease progression for up to 2 years post treatment Time to disease progression, confirmed by bone marrow biopsy.
Treatment-related Mortality Rate Observed during treatment and for 30 days after last dose, so approximately 35 days for the 1 patient treated. As determined by the number of treatment related deaths during study treatment
Quizartinib Tolerability After Allogeneic Hematopoietic Cell Transplantation (alloHCT) or Donor Lymphocyte Infusion (DLI) From Date of First Treatment, up to 2 years Defined as the number of patients who received quizartinib and proceeded to alloHCT or DLI as part of this study and had treatment-related adverse events
Trial Locations
- Locations (5)
HCA Midwest
🇺🇸Kansas City, Missouri, United States
Colorado Blood Cancer Institute
🇺🇸Denver, Colorado, United States
Tennessee Oncology
🇺🇸Nashville, Tennessee, United States
St. David's South Austin Medical Center
🇺🇸Austin, Texas, United States
Texas Transplant Institute
🇺🇸San Antonio, Texas, United States